INS and type 2 diabetes mellitus: Therefore, it has a half-life of about 1 week and is suitable for once a-week administration.[23–25] ONWARDS 2 and ONWARDS 4 are the first 2 Phase III trial to publish clinical data showing that icode is safe and efficacious in patients with T2D suboptimally controlled with basal insulin.[10,21] In these studies, icodec showed non-inferior glycemic control compared with insulin glargine as measured by HbA1c change from baseline to study end point.